Switzerland-based biopharma Basilea has appointed David Veitch as chief commercial officer, effective September 1, 2014.
Veitch will lead the company’s commercial operations, including sales, marketing and pricing.
He joins from Savient Pharmacueticals where he served as president of the company’s’ European operations. It’s at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined Savient.
Veitch’s most senior role at BMS was senior VP for EMEA marketing and brand commercialisation.
Ronald Scott, CEO of Basilea, commented that Veitch’s “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera in Europe in 2015.